Schedule 13D ownership disclosure

ESSA PHARMA INC

Common Shares · CUSIP: 29668H708

Event date: 2025-08-05

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L PReported CIK 0000918923

    Shares: 6,194,145.00 · Class: 13.1%

  • BVF I GP LLCReported CIK 0001803805

    Shares: 6,194,145.00 · Class: 13.1%

  • BIOTECHNOLOGY VALUE FUND II LPReported CIK 0001102444

    Shares: 4,726,743.00 · Class: 9.99%

  • BVF II GP LLCReported CIK 0001803806

    Shares: 4,726,743.00 · Class: 9.99%

  • Biotechnology Value Trading Fund OS LPReported CIK 0001660683

    Shares: 560,797.00 · Class: 1.2%

  • BVF Partners OS Ltd.Reported CIK 0001660684

    Shares: 560,797.00 · Class: 1.2%

  • BVF GP HOLDINGS LLCReported CIK 0001803809

    Shares: 10,920,888.00 · Class: 23.1%

  • BVF PARTNERS L P/ILReported CIK 0001055947

    Shares: 11,668,473.00 · Class: 24.7%

  • BVF INC/ILReported CIK 0001056807

    Shares: 11,668,473.00 · Class: 24.7%

  • LAMPERT MARK NReported CIK 0001233840

    Shares: 11,668,473.00 · Class: 24.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-002132
Form type
SCHEDULE 13D/A
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Aug 07, 2025
Reporting period
Aug 05, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub